ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MDWD MediWound Limited

16.31
0.27 (1.68%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
MediWound Limited NASDAQ:MDWD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.27 1.68% 16.31 16.23 17.25 16.89 15.84 16.27 38,686 21:30:00

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

20/04/2023 9:08pm

Edgar (US Regulatory)




SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
______________________
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
 
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
 
For the month of April 2023
 
Commission File Number: 001-36349
 
MediWound Ltd.
(Translation of registrant’s name into English)
 
42 Hayarkon Street
Yavne, 8122745 Israel
 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Form 20-F  ☒          Form 40-F  ☐
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   __
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   __
 

CONTENTS

Proxy Materials for Annual Shareholder Meeting

Annexed hereto and incorporated herein by reference are copies of the following proxy materials being distributed by MediWound Ltd. (the “Company”) to its shareholders in connection with the Company’s upcoming 2023 annual general meeting of shareholders, which is scheduled to be held on May 31, 2023:

 
1.
Notice of 2023 Annual General Meeting, and Proxy Statement, each dated April 20, 2023, annexed as Exhibit 99.1 hereto.
 
2.
Proxy Card for shareholders of record as of April 21, 2023, annexed as Exhibit 99.2 hereto.
The content of this report on Form 6-K (including the information contained in Exhibits 99.1 and 99.2), is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014, March 24, 2016, March 19, 2018, March 25, 2019, February 25, 2020, May 15, 2021 and August 9, 2022 (Registration Nos. No. 333-195517, 333-210375, 333-223767, 333-230487, 333-236635, 333-255784, and  333-266697, respectively) and on Form F-3 filed with the SEC on May 25, 2022 and March 31, 2023 (Registration Nos. 333-265203 and 333-268297, respectively).


SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  MEDIWOUND LTD.  
       
Date: April 20, 2023
By:
/s/ Boaz Gur-Lavie  
  Name:
Boaz Gur-Lavie  
  Title:
Chief Financial Officer  


EXHIBIT INDEX

The following exhibits are furnished as part of this Form 6-K:



1 Year MediWound Chart

1 Year MediWound Chart

1 Month MediWound Chart

1 Month MediWound Chart